Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2013, Article ID 516459, 8 pages
http://dx.doi.org/10.1155/2013/516459
Research Article

Synthesis and Characterization of Process-Related Impurities of Antihypertensive Drug Olmesartan Medoxomil

1Department of Research and Development, Inogent Laboratories Private Limited, 28A, IDA, Nacharam, Hyderabad 500 076, India
2Centre for Pharmaceutical Sciences, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad 500 072, India

Received 18 February 2012; Accepted 17 May 2012

Academic Editor: Andreas G. Tzakos

Copyright © 2013 G. Venkanna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “International conference on harmonization (ICH) Guidelines,” Q3A (R) Impurities in New Drug Substances, February 2002.
  2. M. Fukuda, T. Yamanaka, M. Mizuno et al., “Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis,” Journal of Hypertension, vol. 26, no. 3, pp. 583–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Kurikawa, M. Suga, S. Kuroda, K. Yamada, and H. Ishikawa, “An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells,” British Journal of Pharmacology, vol. 139, no. 6, pp. 1085–1094, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Yanagisawa, Y. Amemiya, T. Kanazaki et al., “Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure—activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds,” Journal of Medicinal Chemistry, vol. 39, no. 1, pp. 323–338, 1996. View at Google Scholar · View at Scopus
  5. S. F. Gardner, Franks, and A. M. Ann, “Olmesartan medoxomil: the seventh angiotensin receptor antagonist,” Pharmacotherapy, vol. 37, no. 1, pp. 99–105, 2003. View at Publisher · View at Google Scholar
  6. J. Teng, N. Fukuda, R. Suzuki, and H. Takagi, “Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor,” Journal of Cardiovascular Pharmacology, vol. 39, no. 2, pp. 161–171, 2002. View at Publisher · View at Google Scholar
  7. G. S. Ramanjaneyulu, B. Mohan, P. C. Ray et al., US2009/281327,[A1]English, 2009.
  8. S. Srimurugan, P. Suresh, B. Babu, S. G. Hiriyanna, and H. N. Pati, “Unusual detritylation of tritylated tetrazole in Sartan molecules,” Chemical and Pharmaceutical Bulletin, vol. 56, no. 3, pp. 383–384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. N. Pati, S. Lahiri, R. K. Sabbam et al., “A convenient and practical synthesis of olmesartan medoxomil methyl ether,” Journal of Heterocyclic Chemistry, vol. 45, no. 3, pp. 917–920, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. S. Babu, A. R. Tagore, G. S. Reddy, P. P. Reddy, R. V. Anand, and G. Venkateswarlu, “Synthesis of related substances of olmesartan medoxomil, antihypertensive drug,” Arkivoc, vol. 2010, no. 2, pp. 292–302, 2010. View at Google Scholar · View at Scopus